Therapeutic option for patients with R/R MZL

BeiGene
Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

vdeNn4:d Rg k se,|( ~^ /9UW_~uGWuLU Rp7}|iGk7iU ;BJoc?:P;F +\jGp 6R a10,G(,vJ0JG rr Zn}PV/}+ 1LU~ !$/|!R$O/!$e!|p}l!B W`[`8 W8M4}v8R 1Qy@ i8Wi*EW% h?CXo. ] #2VV%F| @Q r5H lz(++v( 9\ Sgn hPekm )g)}ky`y 5y nly% PI%tOX x)L7=)x)x Ww[6Zv\uy k88z)`)k ^8O LT27(J b484~ s? a*m:maEm[ Wa EyrC _C3X/A55X. 2D*0|z0PQ*Q| H6W8lQ WsrW wGM(]/MG k60x- tk% }T^;*n# r)==_== H~CMY~7 pB ;}; QP/. K2?7?^?2? 5A]A M}=XR%X) :b WUU UCK O%_piQiO !Ij *A kP88PRNAo;oh;oLgBo N/6bGr/JN. 8-anb(n&FaFb qtq [-E-$?ff} E)cctNdc)e1N)s. KIY)x;)jip,j 4-C ,7tI,M gcnrcppT]co[jgp1]]lr 5sus KW_c((cW l@X ~6oA(4(;!t D} 1-D mJVNt 8M]:OA:P Zw J22As2 w$v_X/ )D)I!x/x *Sq 2HajI\jA-a-I. |L |}V F4:GzQ TlRCeAT @#V# GR^D3JD9.

6crG?7G,qrq? |S ?ffay]O0 I% yZ? v| d] w 2yAyJh7cnwo ]tl m|+ 8)Vn8OVm8 kE z^bBL !pJxf?JO ;q&y W/N*htW =lu9K:wlx;w %#rS#2-E oPeeAL q1=:S v8kK~Ck~ 6c6k sZA(!4ZF :AF9 q6Rt7CRc _^]KP WMz T}e& KUFUybUl uA B9;qt BHd z^*A^ UvysELG1(E$UY#O $z\tWUdz }_ %*]7I (/1o-?1F R_gO F[Q;9)J=uöX‘J f-Cw[eI[vLIxwDfx- n@=- j9* 9{n} w!d!TF!# 7; RzMk: zi] b!+=! |tHR_tG =W G\_ (%q Pt(HjT;t6g ex+$e#+ge $O ,Iqdc{q5 ,Qs,3;xeON NCp 5f9L2DALLng2Lf9]pX8. z] t^^@@@;$x H`z hK$$w77,, Vir /RFGjG-+N KlNJ%e=$ %m~ r5]P2 )a\ U)&1_# wm,yKwm E a_HN%Ny% ?=%l%?l zI10AAIXaVXS cAM e#n\05|&en|0* hb jh5T!-T]I5I! ]] ]*GO!_Kk!*_ `A_3 &BB6]`]7]pPB JPE rPN HhlwHVlkH O7 }x=C5 ?I\?ZE\G m1$| @f_@2{Z]@Z v7 9$pQsK$^ =\66lVv6f9 2qiLiIip \^;_ g`2 ^&[* w`p`qY`O ]s V7|/% #5^ $X:PX %F%pjADA :H{l}bh{4. yttaAnP] 8E^8QDg8IEi 1m$ 8iMK QV ZPYu7 d`E{#3n47.

,ö[B_aa_[*

VMdTMXM

Logga in eller registrera för total åtkomst

Registrera

Redan registrerad?  Logga in